News | EP Lab | May 21, 2018

Radiofrequency Transseptal Needle Associated With 40 Percent Decrease in Silent Cerebral Embolism

A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.

May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NRG radiofrequency (RF) Transseptal Needle for transseptal punctures was linked to a 40 percent lower incidence of silent acute cerebral embolism in atrial fibrillation (AF) ablation procedure patients.[1] 

The study publication follows a consensus statement recently revised by Heart Rhythm Society and other international societies which suggests that, though the long-term impact of silent cerebral embolism needs investigation, physicians should take the necessary measures to avoid it.[2] These are the first study results to find that a lower incidence could be associated with the type of transseptal needle chosen for ablation procedures.

The study compared the post-procedural MRI scans of 232 patients where AF ablation was done using either the NRG needle or a mechanical needle. Authors suggest there were two differences between the procedures that may contribute to lower risk of silent cerebral embolism.

Advancing the sharp tip of a mechanical needle through a plastic sheath and dilator can create shaved-off plastic particles, which, if entering the bloodstream, may result in embolic material being transferred into the patient's body. The blunt-tipped RF needle does not produce this skiving effect.

In addition, the study showed a 14-minute shorter mean procedure time when using the RF needle, which, as per the authors, could contribute to the lower incidence of silent cerebral embolism. The study authors also suggest the shorter procedure time could lead to cost efficiencies for electrophysiology labs.

"These study findings join the large body of evidence which confirms that using the NRG needle will result in a more predictable procedure and outcome for physicians," said Gareth Davies, Ph.D., research and development manager at Baylis Medical. "This is part of our larger focus on continually identifying the challenges faced by physicians in order to develop innovative solutions to meet the needs of their patients."

The research findings were published in April 2018.

For more information: www.baylismedical.com

References: 

1. Tokuda et al. Radiofrequency Needle for Transseptal Puncture is associated with Lower Incidence of Thromboembolism during Catheter Ablation of Atrial Fibrillation: Propensity score-matched analysis. Heart and Vessels. 10 April 2018. [Epub ahead of print]

2. Calkins et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 Oct;14(10):e275-e444.

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init